stryker corp. - SYK

SYK

Close Chg Chg %
362.42 -4.10 -1.13%

Closed Market

358.33

-4.10 (1.13%)

Volume: 2.00M

Last Updated:

Feb 6, 2026, 3:59 PM EDT

Company Overview: stryker corp. - SYK

SYK Key Data

Open

$362.93

Day Range

354.48 - 364.81

52 Week Range

329.16 - 404.87

Market Cap

$137.93B

Shares Outstanding

382.42M

Public Float

358.80M

Beta

0.88

Rev. Per Employee

N/A

P/E Ratio

43.15

EPS

$8.49

Yield

93.81%

Dividend

$0.88

EX-DIVIDEND DATE

Mar 31, 2026

SHORT INTEREST

N/A

AVERAGE VOLUME

2.11M

 

SYK Performance

1 Week
 
-1.93%
 
1 Month
 
-1.39%
 
3 Months
 
1.79%
 
1 Year
 
-7.40%
 
5 Years
 
51.78%
 

SYK Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 32
Full Ratings ➔

About stryker corp. - SYK

Stryker Corp. is a medical technology company, which engages in the provision of products and services that help improve patient and healthcare outcomes. It operates under the MedSurg and Neurotechnology, and Orthopaedics and Spine segments. The MedSurg and Neurotechnology segment includes surgical equipment and navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment, intensive care disposable products, clinical communication, workflow solutions, products for the treatment of acute ischemic and hemorrhagic stroke, traditional brain, and open skull based surgical procedures, orthobiologic, and biosurgery. The Orthopaedics and Spine segment focuses on implants used in hip and knee joint replacements and trauma and extremity surgeries, and cervical, thoracolumbar, and interbody systems used in spinal injury, deformity, and degenerative therapies. The company was founded by Homer H. Stryker in 1941 and is headquartered in Portage, MI.

SYK At a Glance

Stryker Corp.
1941 Stryker Way
Portage, Michigan 49002
Phone 1-269-385-2600 Revenue 25.12B
Industry Medical Specialties Net Income 3.25B
Sector Health Technology 2025 Sales Growth 11.157%
Fiscal Year-end 12 / 2026 Employees N/A
View SEC Filings

SYK Valuation

P/E Current 43.145
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 41.842
Price to Sales Ratio 5.348
Price to Book Ratio N/A
Price to Cash Flow Ratio 26.63
Enterprise Value to EBITDA 21.281
Enterprise Value to Sales 5.777
Total Debt to Enterprise Value 0.102

SYK Efficiency

Revenue/Employee N/A
Income Per Employee N/A
Receivables Turnover 6.218
Total Asset Turnover 0.553

SYK Liquidity

Current Ratio 1.893
Quick Ratio 1.212
Cash Ratio 0.526

SYK Profitability

Gross Margin 61.443
Operating Margin 22.396
Pretax Margin 17.973
Net Margin 12.924
Return on Assets 7.149
Return on Equity 15.079
Return on Total Capital 8.707
Return on Invested Capital 9.211

SYK Capital Structure

Total Debt to Total Equity 66.276
Total Debt to Total Capital 39.859
Total Debt to Total Assets 31.057
Long-Term Debt to Equity 66.276
Long-Term Debt to Total Capital 39.859
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Stryker Corp. - SYK

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
18.45B 20.50B 22.59B 25.12B
Sales Growth
+7.84% +11.11% +10.23% +11.16%
Cost of Goods Sold (COGS) incl D&A
7.41B 8.00B 8.62B 9.68B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
998.00M 1.03B 1.05B 1.19B
Depreciation
371.00M 393.00M 427.00M 461.00M
Amortization of Intangibles
627.00M 635.00M 623.00M 732.00M
COGS Growth
+15.78% +8.03% +7.63% +12.41%
Gross Income
11.04B 12.49B 13.98B 15.43B
Gross Income Growth
+3.09% +13.17% +11.89% +10.39%
Gross Profit Margin
+59.84% +60.95% +61.87% +61.44%
2022 2023 2024 2025 5-year trend
SG&A Expense
7.31B 8.21B 8.92B 9.81B
Research & Development
1.23B 1.29B 1.41B 1.58B
Other SG&A
6.08B 6.92B 7.50B 8.22B
SGA Growth
+5.18% +12.41% +8.60% +9.96%
Other Operating Expense
- - - -
-
Unusual Expense
853.00M 334.00M 1.30B 751.00M
EBIT after Unusual Expense
2.88B 3.95B 3.76B 4.87B
Non Operating Income/Expense
139.00M 82.00M 124.00M (375.00M)
Non-Operating Interest Income
- 94.00M 75.00M 139.00M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- 337.00M 356.00M 396.00M
Interest Expense Growth
- - +5.64% +11.24%
-
Gross Interest Expense
- 337.00M 356.00M 396.00M
Interest Capitalized
- - - -
-
Pretax Income
2.68B 3.67B 3.49B 4.51B
Pretax Income Growth
+17.62% +36.90% -4.93% +29.27%
Pretax Margin
+14.54% +17.92% +15.45% +17.97%
Income Tax
325.00M 508.00M 499.00M 1.27B
Income Tax - Current - Domestic
- (12.00M) 284.00M 580.00M
Income Tax - Current - Foreign
- 279.00M 430.00M 289.00M
Income Tax - Deferred - Domestic
- (209.00M) (232.00M) (538.00M)
Income Tax - Deferred - Foreign
- 267.00M 26.00M 168.00M
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
2.36B 3.17B 2.99B 3.25B
Minority Interest Expense
- - - -
-
Net Income
2.36B 3.17B 2.99B 3.25B
Net Income Growth
+18.25% +34.22% -5.43% +8.45%
Net Margin Growth
+12.78% +15.44% +13.25% +12.92%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
2.36B 3.17B 2.99B 3.25B
Preferred Dividends
- - - -
-
Net Income Available to Common
2.36B 3.17B 2.99B 3.25B
EPS (Basic)
6.2348 8.3377 7.8556 8.4929
EPS (Basic) Growth
+17.88% +33.73% -5.78% +8.11%
Basic Shares Outstanding
378.20M 379.60M 381.00M 382.20M
EPS (Diluted)
6.1695 8.2486 7.7619 8.4
EPS (Diluted) Growth
+18.28% +33.70% -5.90% +8.22%
Diluted Shares Outstanding
382.20M 383.70M 385.60M 382.20M
EBITDA
4.73B 5.31B 6.11B 6.82B
EBITDA Growth
-0.44% +12.19% +15.11% +11.57%
EBITDA Margin
+25.65% +25.90% +27.05% +27.15%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 431.481
Number of Ratings 32 Current Quarters Estimate 2.997
FY Report Date 03 / 2026 Current Year's Estimate 15.011
Last Quarter’s Earnings 4.47 Median PE on CY Estimate N/A
Year Ago Earnings 13.63 Next Fiscal Year Estimate 16.78
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 26 26 28 25
Mean Estimate 3.00 3.46 15.01 16.78
High Estimates 3.07 3.51 15.10 17.17
Low Estimate 2.92 3.27 14.94 16.46
Coefficient of Variance 1.23 1.34 0.23 0.85

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 18 18 18
OVERWEIGHT 7 7 6
HOLD 6 6 8
UNDERWEIGHT 1 1 1
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Stryker Corp. - SYK

Date Name Shares Transaction Value
Nov 21, 2025 Preston Wells VP, Chief Financial Officer 6,694 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $365.88 per share 2,449,200.72
Feb 28, 2025 Ronda E. Stryker Director 3,299,776 Bona fide gift 0.00
Feb 28, 2025 Ronda E. Stryker Director 3,807,334 Bona fide gift 0.00
Feb 28, 2025 Yin C. Becker VP, Chief Corp Affairs Officer 35,729 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $96.64 per share 3,452,850.56
Feb 28, 2025 Yin C. Becker VP, Chief Corp Affairs Officer 32,798 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $391.74 per share 12,848,288.52
Feb 28, 2025 Yin C. Becker VP, Chief Corp Affairs Officer N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 20, 2025 Allan C. Golston Director 18,500 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $122.51 per share 2,266,435.00
Feb 20, 2025 Allan C. Golston Director 17,353 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $385.18 per share 6,684,028.54
Feb 20, 2025 Allan C. Golston Director 14,895 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $383.07 per share 5,705,827.65
Feb 20, 2025 Allan C. Golston Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00

Stryker Corp. in the News